Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Fleshner

Showing results (191-200 of 292) with videos related to

Pageof 30
Sort By:
Cancer Research Communications|June 30, 2026
Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort StudyRashid K Sayyid, Raj Tiwari, Bo Zhang, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical CystectomyPeter J Boström, Tuomas Mirtti, Bas van Rhijn, et al.
BJU International|April 22, 2011
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohortGreg Trottier, Monique J Roobol, Nathan Lawrentschuk, et al.
European Urology Oncology|July 2, 2020
Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate CancerHarry C Brastianos, Jure Murgic, Adriana Salcedo, et al.
Lancet Regional Health. Americas|October 3, 2025
Is it time for Canada to revisit its approach to prostate cancer screening?David-Dan Nguyen, Aisha Lofters, Christopher J D Wallis, et al.
Urology|September 19, 2013
Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohortBimal Bhindi, David Margel, Greg Trottier, et al.
Epigenomics|September 2, 2020
Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatmentMadonna R Peter, Misha Bilenky, Ruth Isserlin, et al.
European Urology|January 8, 2011
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancerAntonio Finelli, Greg Trottier, Nathan Lawrentschuk, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 20, 2025
Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imagingRavi Kumar, Katherine Lajkosz, Ur Metser, et al.
Urologic Oncology|August 8, 2017
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicionBimal Bhindi, Haiyan Jiang, Cedric Poyet, et al.
Pageof 30

Showing results (191-200 of 292) with videos related to

Sort By:
Pageof 30
Cancer Research Communications|June 30, 2026
Association of Cumulative Proton Pump Inhibitor Use with Prostate Cancer Risk and Outcomes: A Population-Based Cohort StudyRashid K Sayyid, Raj Tiwari, Bo Zhang, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical CystectomyPeter J Boström, Tuomas Mirtti, Bas van Rhijn, et al.
BJU International|April 22, 2011
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohortGreg Trottier, Monique J Roobol, Nathan Lawrentschuk, et al.
European Urology Oncology|July 2, 2020
Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate CancerHarry C Brastianos, Jure Murgic, Adriana Salcedo, et al.
Lancet Regional Health. Americas|October 3, 2025
Is it time for Canada to revisit its approach to prostate cancer screening?David-Dan Nguyen, Aisha Lofters, Christopher J D Wallis, et al.
Urology|September 19, 2013
Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohortBimal Bhindi, David Margel, Greg Trottier, et al.
Epigenomics|September 2, 2020
Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatmentMadonna R Peter, Misha Bilenky, Ruth Isserlin, et al.
European Urology|January 8, 2011
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancerAntonio Finelli, Greg Trottier, Nathan Lawrentschuk, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 20, 2025
Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imagingRavi Kumar, Katherine Lajkosz, Ur Metser, et al.
Urologic Oncology|August 8, 2017
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicionBimal Bhindi, Haiyan Jiang, Cedric Poyet, et al.
Pageof 30